Meroni P L, Del Papa N, Borghi M O
Istituto di Medicina Interna, University of Milan-IRCCS Policlinico, Italy.
Int Arch Allergy Immunol. 1996 Dec;111(4):320-5. doi: 10.1159/000237387.
A lot of attention has recently been paid to antiphospholipid and antiendothelial cell antibodies as serological markers for systemic autoimmune diseases. Antiphospholipid antibodies appear to display a prognostic value for recurrent thrombosis and fetal loss both in a subset of systemic lupus erythematosus and in patients with the primary antiphospholipid syndrome. The range of diagnostic tests for the antiphospholipid syndrome is now becoming larger with the inclusion of assays suitable for identifying antibodies against phospholipids other than cardiolipin and especially against phospholipid-binding proteins. Antiendothelial cell antibodies have been suggested as serological markers for immune-mediated vascular damage. In vitro and in vivo experimental models as well as epidemiological studies seem to support this. However, the assays for their detection still lack standardization.
最近,抗磷脂抗体和抗内皮细胞抗体作为系统性自身免疫性疾病的血清学标志物受到了广泛关注。抗磷脂抗体似乎对系统性红斑狼疮的一个亚组以及原发性抗磷脂综合征患者的复发性血栓形成和胎儿丢失具有预后价值。随着适用于鉴定除心磷脂以外的磷脂抗体,特别是抗磷脂结合蛋白抗体的检测方法的纳入,抗磷脂综合征的诊断检测范围现在越来越大。抗内皮细胞抗体已被认为是免疫介导的血管损伤的血清学标志物。体外和体内实验模型以及流行病学研究似乎支持这一点。然而,检测它们的方法仍缺乏标准化。